While the world waits with bated breath for a safe, effective, widely available COVID-19 vaccine, another option for ending the pandemic has been staring us in the face. A government-led industrial and coordination strategy to achieve universal testing could bring the crisis to an end in a matter of months. LONDON – Research to develop a safe, effective, and widely available COVID-19 vaccine is advancing rapidly. But when it will happen is not clear. Much depends on how we govern the production and distribution of new drugs. While the World Health Organization’s COVID-19 Technology Access Pool promises to foster accessibility, the actual availability of vaccines and treatments also will hinge on local manufacturing
Topics:
Mariana Mazzucato considers the following as important:
This could be interesting, too:
Real Vision writes Bitcoin: “Finding Its Seat at the Macro Table”: Real Vision Daily Briefing- Oct 27, 2020
Menzie Chinn writes Guest Contribution: “The Relative Performance of the U.S. Federal Debt”
David writes ND COVID Moving averages, 27 October 2020 Update
FT Alphaville writes Global gosbankification risk is now at orange
While the world waits with bated breath for a safe, effective, widely available COVID-19 vaccine, another option for ending the pandemic has been staring us in the face. A government-led industrial and coordination strategy to achieve universal testing could bring the crisis to an end in a matter of months.
LONDON – Research to develop a safe, effective, and widely available COVID-19 vaccine is advancing rapidly. But when it will happen is not clear. Much depends on how we govern the production and distribution of new drugs. While the World Health Organization’s COVID-19 Technology Access Pool promises to foster accessibility, the actual availability of vaccines and treatments also will hinge on local manufacturing capacity, which in many countries has been eroded by deindustrialization.
Moreover, while universal testing remains a feasible, cost-effective, and immediately available method of managing the pandemic until a vaccine arrives, this approach also requires manufacturing capacity and sound governance in the public interest. Yet even in advanced economies, over-reliance on the private sector may prevent governments from maximizing test production and deployment. For example, the British government has proposed a “moon shot” testing program, yet its actual strategy needs clarification.
Such a mission-oriented approach requires a holistic, systems-level perspective, particularly when it comes to “wicked problems” like public-health crises and climate change, which involve a wide range of complex socioeconomic and technological issues. Implementing universal testing will require contributions from a sprawling network of actors and institutions. To be truly effective, any such program must be designed to generate systemic resilience and public value.
As has been demonstrated by the Nobel laureate economist Paul Romer, the epidemiologist Michael Mina, a recent IMF